:format(webp)/cdn.mskdoctors.com/storage/2026/8/qaIZGeooLUJtaK5Ndmgn8681psd7lMhV.jpg)
ChondroFiller versus hyaluronic acid for cartilage defectsChondroFiller fills discrete cartilage defects using a cell-recruiting scaffold; hyaluronic acid treats diffuse osteoarthritis through joint lubrication. They address different pathologies, and the choice depends on imaging, not on how much pain a patient experiences.ChondroFiller fills discrete cartilage defects using a cell-recruiting scaffold; hyaluronic acid treats diffuse osteoarthritis through joint lubrication. They address different pathologies, and the choice depends on imaging, not on how much pain a patient experiences.
:format(webp)/cdn.mskdoctors.com/storage/2026/7/S6fB5FURIu0CvCfaH3a2BsSKF1F6KZtW.jpg)
Who qualifies for ChondroFiller Liquid Cartilage injectionChondroFiller is an outpatient ultrasound-guided injection—not surgery—of acellular collagen that recruits the patient's own progenitor cells to regenerate cartilage damage, without upper age or defect-size limits.ChondroFiller is an outpatient ultrasound-guided injection—not surgery—of acellular collagen that recruits the patient's own progenitor cells to regenerate cartilage damage, without upper age or defect-size limits.
:format(webp)/cdn.mskdoctors.com/storage/2026/7/zKztwrt8KaoDb73OWJr53Zg4tZADHBlu.jpg)
What ChondroFiller's CE approval means for UK patientsChondroFiller recruits the body's progenitor cells to repair focal cartilage defects, achieving symptom relief in 70–85% of selected patients, though it offers no benefit for widespread osteoarthritis.ChondroFiller recruits the body's progenitor cells to repair focal cartilage defects, achieving symptom relief in 70–85% of selected patients, though it offers no benefit for widespread osteoarthritis.
:format(webp)/cdn.mskdoctors.com/storage/2026/7/rgOU5joVFIvQSkaY3S921m8v6ZjDLgSd.jpg)
Who qualifies for a ChondroFiller injectionChondroFiller targets ICRS Grade III–IV cartilage damage, where more than half the cartilage is lost or bone is exposed. Delivered as an ultrasound-guided outpatient injection, the collagen scaffold recruits the patient's own progenitor cells to initiate repair.ChondroFiller targets ICRS Grade III–IV cartilage damage, where more than half the cartilage is lost or bone is exposed. Delivered as an ultrasound-guided outpatient injection, the collagen scaffold recruits the patient's own progenitor cells to initiate repair.
:format(webp)/cdn.mskdoctors.com/storage/2026/7/92K6tqyBnZDrB97bjQM5FimjqPsDB7mw.jpg)
How long ChondroFiller results lastChondroFiller's collagen scaffold biodegrades within 6–24 months, yet provides lasting clinical benefit by recruiting the patient's own cells to form repair tissue; 70–85% of well-selected patients maintain meaningful symptom relief at three to five years.ChondroFiller's collagen scaffold biodegrades within 6–24 months, yet provides lasting clinical benefit by recruiting the patient's own cells to form repair tissue; 70–85% of well-selected patients maintain meaningful symptom relief at three to five years.
:format(webp)/cdn.mskdoctors.com/storage/2026/6/2WlwnJj0faCPyw0ya8IAE2HzUDpZMpBK.jpg)
Who qualifies for ChondroFiller injectionChondroFiller targets Grade III and IV cartilage damage—focal defects or distributed osteoarthritis—using a collagen scaffold to support biological repair across both presentations, provided joint mechanical stability remains intact.ChondroFiller targets Grade III and IV cartilage damage—focal defects or distributed osteoarthritis—using a collagen scaffold to support biological repair across both presentations, provided joint mechanical stability remains intact.
:format(webp)/cdn.mskdoctors.com/storage/2026/6/57s18HJqAXR5l5fNKN3AOCVygSdgfLOY.jpg)
ChondroFiller durability vs Arthrosamid and hyaluronic acidChondroFiller's collagen scaffold breaks down in six to twenty-four months, but the clinical benefit lasts one to five years or longer because the material recruits the patient's own progenitor cells to support cartilage repair, not to act as permanent filling.ChondroFiller's collagen scaffold breaks down in six to twenty-four months, but the clinical benefit lasts one to five years or longer because the material recruits the patient's own progenitor cells to support cartilage repair, not to act as permanent filling.
:format(webp)/cdn.mskdoctors.com/storage/2026/6/Lj6L1IaL5TBE3CuCl6wA8ci1T5bHoA72.jpg)
ChondroFiller success rates in practiceChondroFiller, which recruits a patient's own cells to fill cartilage defects, produces meaningful pain reduction and improved joint function in 70–85% of patients within one to five years; but success depends on selecting younger patients with focal defects in otherwise healthy joints.ChondroFiller, which recruits a patient's own cells to fill cartilage defects, produces meaningful pain reduction and improved joint function in 70–85% of patients within one to five years; but success depends on selecting younger patients with focal defects in otherwise healthy joints.
